NatDac is the Generic Version of Dakinza (Daclatasvir)

On 17th December 2105  Natco Pharma got approval for generic Daclatasvir Dihydrochloride (“Daclatasvir”) tablets, NatDac 30mg & NatDac 60mg, from Drugs Controller General (India).

Daclatasvir (NatDac) is the first-in-class NS5A inhibitor used in combination with Sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat HCV patient subsets.

U.S. Food and Drug Administration approved NatDac (Daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections on July 24, 2015 . NATDAC (Daclatasvir) is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.



  • Brand Name: Natdac
  • Content: Daclatasvir
  • Manufactured by: Natco Pharma Ltd.
  • Strengths: 30mg and 60 mg
  • Form: Tablets
  • Packing: Pack of 28 Tablets


Daclatasvir (NatDac) is on the World Health Organization’s List of Essential Medicines, a list of the most important medications needed in a basic health system.


  • Dosage and Administration :Daclatasvir
    Download Daclatasvir Prescribing information
    NatDac (Daclatasvir) is available in 30 and 60mg tablets, and the usual dose is 60mg once daily with or without food.
    NatDac (Daclatasvir) must be used in combination with other hepatitis C medications and is not effective if taken alone.

    Combined with:Length of treatment

    Genotype  1


    Daclatasvir & sofosbuvir

    12 weeks (no cirrhosis)

    24 weeks (with cirrhosis)

    Genotype 2


    Daclatasvir & sofosbuvirNo recommendation regarding which patients with genotype 2 HCV are eligible for treatment with daclatasvir due to limited evidence.

    Genotype 3


    Daclatasvir & sofosbuvir & ribavirin24 weeks (with cirrhosis or treatment-experienced)

    Genotype 4


    Daclatasvir & sofosbuvir


    Daclatasvir & pegylated interferon & ribavirin

    12 weeks (no cirrhosis)

    24 weeks (with cirrhosis)

    24 or 48 weeks

    People with HCV genotypes 1 or 4 who are being treated for the first time and do not have liver cirrhosis should take daclatasvir plus sofosbuvir for 12 weeks. Due to limited clinical trial data, there is still uncertainty about the best way to treat people with genotypes 2, 3 or 4.

    Treatment should be managed by a doctor who has experience treating hepatitis C.
    NatDac (Daclatasvir) is to be taken strictly under Medical  Supervision of Hepatologist/Gastroenterologist/HCV  only